December 13, 2021

Gil M. Labrucherie Chief Operating Officer and Chief Financial Officer Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, CA 94158

> Re: Nektar Therapeutics Form 10-K for the

> > Filed February 26,

Fiscal Year Ended December 31, 2020

2021

File Number

000-24006

Dear Mr. Labrucherie:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding

any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance

Office of Life Sciences